结合临床病理与基因表达模型识别I/IIA期黑色素瘤高复发风险患者
研究评估CP-GEP模型(结合Breslow厚度、年龄及8个基因表达)在580例I/IIA期皮肤黑色素瘤患者中的预后价值,主要终点为5年无复发生存。CP-GEP识别出47%的高危患者,其5年RFS为74%(95%CI 67%-80%),显著低于低危组的89%(95%CI 84%-93%),HR=2.98(95%CI 1.78-4.98),P<0.0001。高危组复发多发生在3年内。
要点
- CP-GEP模型可识别I/IIA期黑色素瘤中47%的高复发风险患者。
- 高危组5年RFS为74%,低危组为89%,HR=2.98,P<0.0001。
- 高危组复发多集中在术后3年内,或可考虑辅助治疗。
核心结论
- CP-GEP模型可用于识别I/IIA期黑色素瘤患者中疾病复发高风险人群,这些患者可能从辅助治疗中获益。
研究设计与样本
- 使用837例连续原发性皮肤黑色素瘤的存档标本评估CP-GEP预后性能。
- CP-GEP模型结合Breslow厚度、患者年龄及原发肿瘤中8个基因的表达。
- 针对580例I/IIA期患者,按CP-GEP分为高危和低危组,主要终点为5年无复发生存(RFS)。
主要发现
- 在I/IIA期患者中,CP-GEP高危组占47%,其5年RFS为74%(95%CI 67%-80%)。
- 低危组5年RFS为89%(95%CI 84%-93%)。
- 高危组与低危组比较,HR=2.98(95%CI 1.78-4.98),P<0.0001。
- 高危组中复发者最可能在最初3年内发生复发。
临床怎么用
- 对I/IIA期黑色素瘤患者,可考虑使用CP-GEP模型进行复发风险分层。
- CP-GEP高危患者可能作为辅助治疗的候选人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with stage I/IIA cutaneous melanoma (CM) are currently not eligible for adjuvant therapies despite uncertainty in relapse risk. Here, we studied the ability of a recently developed model which combines clinicopathologic and gene expression variables (CP-GEP) to identify stage I/IIA melanoma patients who have a high risk for disease relapse. PATIENTS AND METHODS: Archival specimens from a cohort of 837 consecutive primary CMs were used for assessing the prognostic performance of CP-GEP. The CP-GEP model combines Breslow thickness and patient age, with the expression of eight genes in the primary tumour. Our specific patient group, represented by 580 stage I/IIA patients, was stratified based on their risk of relapse: CP-GEP High Risk and CP-GEP Low Risk. The main clinical end-point of this study was five-year relapse-free survival (RFS). RESULTS: Within the stage I/IIA melanoma group, CP-GEP identified a high-risk patient group (47% of total stage I/IIA patients) which had a considerably worse five-year RFS than the low-risk patient group; 74% (95% confidence interval [CI]: 67%-80%) versus 89% (95% CI: 84%-93%); hazard ratio [HR] = 2.98 (95% CI: 1.78-4.98); P < 0.0001. Of patients in the high-risk group, those who relapsed were most likely to do so within the first 3 years. CONCLUSION: The CP-GEP model can be used to identify stage I/IIA patients who have a high risk for disease relapse. These patients may benefit from adjuvant therapy.
引用
- Eggermont AMM, Bellomo D, Arias-Mejias SM, et al. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. Eur J Cancer. 2020. PMID: 33032086. doi:10.1016/j.ejca.2020.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。